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dTo the Editor: Chronic heart failure (HF) is a significant problem
in the United States, affecting 5.7 million Americans. Studies have
consistently demonstrated substantial racial and ethnic disparities
in the use of guideline-recommended device therapies related to
HF care. For example, although blacks have the highest age-
adjusted rates of sudden cardiac arrest (1), they remain significantly
less likely than their white counterparts to receive an implantable
cardioverter-defibrillator (ICD) (2). Cardiac resynchronization
therapy with defibrillation (CRT-D) represents another important
therapeutic option for those with HF. The use of CRT-D can
significantly reduce rehospitalizations and all-cause mortality while
improving quality of life and functional status (3); however, blacks
and Hispanics have historically been less likely to receive CRT-D
than whites (4). By using the National Cardiovascular Data
Registry’s ICD Registry, we compared trends in CRT-D use
among potentially eligible patients receiving an ICD to determine
whether racial and ethnic disparities have changed over time.
We queried the ICD Registry for patients eligible for CRT-D
on the basis of New York Heart Association functional class III or
IV symptoms, left ventricular ejection fraction (LVEF) 35%,
ative QRS width 120 ms, and receipt of optimal medical
herapy between April 2006 and March 2010. Optimal medical
herapy was defined as treatment with a beta-blocker and either an
ngiotensin-converting enzyme inhibitor or an angiotensin recep-
or blocker. Individual sites were responsible for establishing and
ubmitting the race and ethnicity of patients receiving a device. We
xcluded patients who had a previous ICD or who required
picardial lead placement, who did not meet the criteria for the
RT-D use, or whose ICD type was unknown. We examined the
se of CRT-D over different time periods and tested the trend
sing the Cochran–Armitage test among the subgroups deter-
ined by race. Interactions between race and time with the use of
RT-D were examined using a hierarchical logistic model to see
hether the time trends are different among different race groups.
A final study population of 107,096 patients was identified from
ases entered between 2006 and 2010. Of these, 87,692 (81.9%)
eceived CRT-D. In the overall study population, the mean age
as 70.7 years, 70.1% of the patients were male, and 83.8% were
hite. The mean LVEF was 23.7%. In the overall study popula-
ion, the use of CRT-D in eligible patients significantly increased
rom 80.4% in the first year to 84.0% in the fourth year (p 0.001)
Table 1). Among eligible whites, blacks, and Hispanics, there was
significant increase in CRT-D use over the study period. After
djusting for age, race, gender, atrial fibrillation/atrial flutter,
erebrovascular disease, chronic lung disease, diabetes, ischemic
eart disease, duration of symptom since initial HF onset, prior oospitalizations for HF, previous myocardial infarction, LVEF,
RS duration, creatinine, sodium, brain natriuretic peptide, hos-
ital owner, hospital region, electrophysiologist operator ICD
raining, physician volume, and the patients’ clustering among
ospitals in the hierarchical model, blacks and Hispanics remained
ess likely to receive CRT-D compared with whites (black vs.
hite odds ratio: 0.69; 95% confidence interval: 0.65 to 0.73, p 
.001; Hispanic vs. white odds ratio: 0.84; 95% confidence
nterval: 0.78 to 0.91; p  0.001). After adjustment, the effect of
ime on CRT-D use in eligible patients did not significantly vary
ccording to the level of race/ethnicity (p  0.68). In a sensitivity
nalysis of racial and ethnic subgroups restricted to Medicare
atients only, the temporal trends among each subgroup persisted
whites: p  0.001, blacks: p  0.02), although these were not
ignificant among Hispanics (p  0.22).
Underlying racial and ethnic differences in treatment patterns
ave been shown to contribute to the overall underuse of CRT-D
4), as is true for other cardiovascular technologies. Similar
isparities have been shown for other interventions in cardiovas-
ular care, including coronary artery bypass grafting, cardiac
atheterization, and ICD use (5). The use of these technologies has
ncreased over time, but underlying treatment gaps have persisted
cross racial and ethnic lines. Before this study, it was unknown
hether CRT-D, a more recent technology to emerge with
idespread applications, has diffused unevenly over time as pre-
eding technologies have. Our analysis of 107,096 patients in the
CD Registry indicates that although adherence to this recom-
endation has improved over time, the widespread application of
RT-D in eligible patients is hampered by the same underuse in
acial and ethnic subgroups that has hindered the diffusion of other
ardiovascular technologies.
To improve the quality of care for patients with advanced HF,
urther initiatives are needed that broaden the use of CRT-D in
ligible patients overall, but particularly those belonging to racial
nd ethnic subgroups. Several factors that account for these
ifferences (i.e., informed and noninformed personal preferences,
rovider biases, geographic variations, and access to care) need to
e addressed. Increasing awareness among patients and providers
bout the benefits of CRT-D is an important mechanism by which
he underuse in appropriate patients can be reduced. Likewise,
ools that enable health care providers to systematically identify
ligible patients at the point of care can improve implementation.
ast, quality improvement programs and performance measures
hat help practices benchmark their quality can help reduce
ifferences in care. Among such initiatives, the American College
f Cardiology has established the Coalition to Reduce Racial and
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unchanged trends in care.
It is important to note that although the Centers for Medicare
& Medicaid Services mandates participation in the ICD Registry
for hospitals performing ICD and CRT-D implantations, data are
not available on those patients who might be eligible but have not
been referred for or received an ICD. Likewise, those patients who
were offered therapy, but declined, are not included. Also, data are
not available to identify cases in which CRT-D was planned but
may have been aborted because of technical limitations; regardless,
these data would not have been affected by patient race or
ethnicity.
The use of CRT-D seems to be improving in the overall
population and in racial and ethnic subgroups; however, disparities
in the use of CRT-D have remained over time. Future efforts to
improve the broad and systematic use of CRT-D in eligible
patients are needed to minimize differences in care and improve
the treatment of patients with advanced HF.
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CRT-D Implantation Rates in Eligible Patients Over TimeTable 1 CRT-D Implantation Rates in Eligible Patients Over Time
Year First Year Second Year
Overall 21,758 (80.35) 21,957 (81.27)
Race
White 17,833 (80.99) 17,858 (82.27)
Black 2,306 (77.54) 2,324 (77.06)
Hispanic 1,091 (76.51) 1,201 (76.21)
Other race 528 (80.24) 574 (79.72)
Values are n (%).
CRT-D  cardiac resynchronization therapy with defibrillation.elevant to the contents of this paper to disclose. eEFERENCES
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Letters to the Editor
Atrioventricular Nodal
Ablation in Heart Failure:
The Picture Is Clear But Incomplete
I would like to offer 2 comments on the systematic review by
Ganesan et al. (1) and the accompanying editorial by Gasparini
and Galimberti (2). First, the review suggests that atrioventricular
nodal ablation (AVNA) in patients who have atrial fibrillation
(AF) and biventricular pacing may reduce all-cause mortality.
Calculations based on the studies summarized in Tables 1 and 2
(1) showed that all-cause mortality in patients who had undergone
AVNA was 19 of 189 (about 10%) and 65 of 261 (about 25%); that
is, the number needed to treat (NNT) was approximately 7 over a
variable median follow-up of 6 to 34 months. These results are
indeed striking, particularly compared with results of randomized
trials of biventricular pacing in sinus rhythm versus medical
therapy alone (245 of 1,472 [about 17%] vs. 231 of 1,129 [about
20%]; that is, a 3% absolute reduction in all-cause mortality (3).
Even at 3 years, the NNT to prevent 1 death was 9 based on the
data from the Cardiac Resynchronization–Heart Failure study (4).
Although it is possible that the benefit of increasing the percent
biventricular pacing in patients with AF from85% (the criterion for
VNA in the largest study included in the review) to close to 100%
ith AVNA may exceed that of patients in sinus rhythm, it is more
lausible that the benefit of AVNA reported in this review is an
Third Year Fourth Year p Value
22,119 (81.97) 21,858 (84.02) 0.001
17,989 (82.82) 17,701 (84.84) 0.001
2,367 (78.22) 2,354 (81.09) 0.001
1,140 (77.18) 1,134 (78.97) 0.044
623 (81.76) 669 (82.39) 0.091xaggeration of the “true” benefit. Nonrandomized studies, particu-
